Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SFM | 8-K | bearish | 6/10 | Sprouts Farmers Market reported Q3 2026 net sales of $2.30 billion (+5% YoY) but comparable store sales declined 0.9% an | Oct 28, 2026 |
| SPGI | 144 | neutral | 2/10 | Steven J. Kemps, an officer of S&P Global, filed a Form 144 notice of intent to sell 4,455 shares of common stock with a | Oct 28, 2026 |
| MDXG | 8-K | bearish | 6/10 | MiMedx reported Q3 2026 net sales of $62M, down 45% YoY from $114M, driven by a 71% decline in Wound sales due to Medica | Oct 28, 2026 |
| IZEA | DEF 14A | neutral | 3/10 | IZEA Worldwide, Inc. filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder votes on dire | Oct 28, 2026 |
| WOLF | 8-K | neutral | 3/10 | Wolfspeed held its 2026 Annual Meeting on October 27, 2026, where all seven director nominees were elected, the 2026 Emp | Oct 28, 2026 |
| MDXG | PRESS-RELEASE | bearish | 6/10 | MiMedx reported Q3 2026 net sales of $62M, down 45% YoY from $114M, driven by a 71% decline in Wound Care sales due to M | Oct 28, 2026 |
| FIX | 8-K | neutral | 3/10 | Comfort Systems USA filed an 8-K to post an investor presentation on its website. The presentation highlights strong YTD | Oct 28, 2026 |
| ALGN | 8-K | neutral | 3/10 | Align Technology announced a CEO succession plan: Jennifer L. Davis, former CEO of P&G's Global Healthcare business, wil | Oct 28, 2026 |
| ADIL | PRESS-RELEASE | neutral | 5/10 | Adial Pharmaceuticals changed its name to Azora Therapeutics and will begin trading under ticker AZR on October 29, 2026 | Oct 28, 2026 |
| OBK | 8-K | bullish | 6/10 | Origin Bancorp reported Q3 2026 net income of $37.8M ($1.22 diluted EPS), up 11.6% from Q2 2026, with NIM-FTE expanding | Oct 28, 2026 |
| TMUS | 8-K | bullish | 6/10 | T-Mobile reported Q3 2026 results with diluted EPS of $3.22, above the consensus estimate of $2.91, and total revenues o | Oct 28, 2026 |
| REPL | 144 | neutral | 2/10 | Director Veleka Peeples-Dyer filed a Form 144 notice of intent to sell 12,000 shares of Replimune Group common stock, va | Oct 28, 2026 |
| MYRG | 8-K | bullish | 6/10 | MYR Group reported record Q3 2026 revenue of $1.26B (up 32.5% YoY) and diluted EPS of $3.82 (up 86.3% YoY), both well ab | Oct 28, 2026 |
| FORM | 8-K | bullish | 6/10 | FormFactor reported Q3 2026 revenue of $280.5M (up 38.4% YoY) and non-GAAP EPS of $1.04, both exceeding the high end of | Oct 28, 2026 |
| MGYR | PRESS-RELEASE | bullish | 5/10 | Magyar Bancorp reported fiscal Q4 2026 net income of $3.3M, up 31% YoY, and full-year net income of $12.6M, up 29% YoY, | Oct 28, 2026 |
| NEWT | PRESS-RELEASE | bearish | 5/10 | NewtekOne reported Q3 2026 EPS of $0.34, missing the $0.39 consensus estimate by 12.8%, while revenue of $71.8M (total i | Oct 28, 2026 |
| HSHP | SC 13G/A | neutral | 2/10 | Drew Holdings Ltd. and Tor Olav Troim filed an amended Schedule 13G disclosing beneficial ownership of 10,505,732 common | Oct 28, 2026 |
| MDXG | PRESS-RELEASE | bullish | 5/10 | MiMedx Group entered into a patent license agreement with an unnamed wound care competitor, receiving a total of $25 mil | Oct 28, 2026 |
| SCQC | PRESS-RELEASE | neutral | 3/10 | SPACCircle Acquisition Corp. closed its IPO of 10 million units at $10.00 per unit, raising $100 million in gross procee | Oct 28, 2026 |
| ALGN | 8-K | neutral | 5/10 | Align Technology reported Q3 2026 revenue of $1.015B, up 1.9% YoY, and non-GAAP EPS of $2.80, slightly above the $2.76 c | Oct 28, 2026 |
| KYMR | PRESS-RELEASE | neutral | 5/10 | Kymera Therapeutics announced it will present Phase 1 clinical trial results for KT-579, a first-in-class oral IRF5 degr | Oct 28, 2026 |
| OFLX | 8-K | bearish | 5/10 | Omega Flex reported Q3 2026 earnings: net sales for the quarter rose 6.0% YoY to $25.7M, but net income fell 36.0% to $2 | Oct 28, 2026 |
| WSBK | 8-K | neutral | 4/10 | Winchester Bancorp reported net income of $1.3 million ($0.14 per share) for the quarter ended September 30, 2026, up fr | Oct 28, 2026 |
| MIRA | 8-K | neutral | 4/10 | MIRA Pharmaceuticals announced initial positive proof-of-concept results from a pilot study of its oral obesity drug can | Oct 28, 2026 |
| BETA | 144 | neutral | 3/10 | Kyle Clark, an officer of BETA Technologies, filed a Form 144 notice of intent to sell 10,000 shares of common stock thr | Oct 28, 2026 |
| BILI | 6-K | neutral | 4/10 | Bilibili shareholders approved a special resolution authorizing a $200 million share repurchase from Tencent, concurrent | Oct 28, 2026 |
| ELAB | 8-K | neutral | 2/10 | PMGC Holdings Inc. (ELAB) filed an 8-K furnishing two investor presentations: a corporate overview of its diversified ho | Oct 28, 2026 |
| SUPV | 3 | neutral | 2/10 | Juan Cruz Piccardo filed a Form 3 initial statement of beneficial ownership with the SEC, reporting stock options to acq | Oct 28, 2026 |
| FORM | PRESS-RELEASE | bullish | 6/10 | FormFactor reported Q3 2026 revenue of $280.5M (up 38.4% YoY) and non-GAAP EPS of $1.04, both above consensus estimates | Oct 28, 2026 |
| MLAB | PRESS-RELEASE | neutral | 2/10 | Mesa Laboratories announced it will release fiscal second quarter 2027 results on November 9, 2026, after market close, | Oct 28, 2026 |